AUSTIN, Texas, April 16, 2018 /PRNewswire/ — Elios Therapeutics, a biopharmaceutical company developing innovative particle-delivered dendritic cell cancer vaccines, today announced that new interim data from the ongoing Phase 2b clinical trial of the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine in patients with stage III and IV, resected melanoma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1 – 5, 2018 in Chicago, Illinois.
The following abstract will be featured at a poster session:
Title: “Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients“
- Presenter: George E. Peoples, M.D., FACS
- Data/Time: Monday, June 4, 2018 from 1:15 PM – 4:45 PM CDT
- Session: Melanoma/Skin Cancers Poster Session – Hall A
The TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine is an autologous, personalized, therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer. TLPLDC is made from a patient’s own tumor and dendritic cells – the most potent antigen-presenting cells in the body. Once TLPLDC is injected, the tumor lysate-loaded dendritic cells present the tumor antigens to the immune system, stimulating the induction of tumor-specific, activated T cells that are able to find and destroy tumor cells that may remain in the body. TLPLDC is currently being studied as a monotherapy and in combination with standard of care checkpoint inhibitor therapy in a Phase 2b clinical trial for the treatment of late-stage melanoma at leading academic cancer centers in the United States.
About Elios Therapeutics, LLC
Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product, TLPLDC, is a personalized therapeutic cancer vaccine designed to attack cancer cells by igniting innate and adaptive immune responses which increase a patient’s own production of T cells to fight their specific cancer. For more information, please visit www.eliostherapeutics.com.
This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, status and results of clinical trials, size of patient population, plans, outcomes of product development efforts, and objectives of management for future operations, may be deemed to be forward‐looking statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes.
These forward‐looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward‐looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward‐looking statements as a prediction of actual results. None of these forward‐looking statements constitutes a guarantee of the future occurrence of such events or of actual results. These statements are based on data, assumptions, and estimates that the Company believes are reasonable.
The forward‐looking statements contained in this document are made only as of the date hereof. Except as otherwise required by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this document to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions, or circumstances on which any forward‐looking statement contained in this document is based.
Elixir Health Public Relations
+1 (201) 723-5805
View original content with multimedia:http://www.prnewswire.com/news-releases/elios-therapeutics-to-present-interim-phase-2b-results-of-tlpldc-a-personalized-therapeutic-cancer-vaccine-for-the-treatment-of-melanoma-at-the-2018-american-society-of-clinical-oncology-asco-annual-meeting-300630632.html
SOURCE Elios Therapeutics, LLC
To post and circulate your own press release on FIR and the eTN Network please click here